The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?

Rudolf A. Werner, Alexander Weich, Malte Kircher, Lilja B. Solnes, Mehrbod S. Javadi, Takahiro Higuchi, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe, Constantin Lapa

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.

Original languageEnglish
Pages (from-to)6088-6100
Number of pages13
JournalTheranostics
Volume8
Issue number22
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • Neuroendocrine tumor
  • PRRT
  • Peptide receptor radionuclide therapy
  • Somatostatin receptor
  • Theranostics

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Fingerprint Dive into the research topics of 'The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?'. Together they form a unique fingerprint.

  • Cite this

    Werner, R. A., Weich, A., Kircher, M., Solnes, L. B., Javadi, M. S., Higuchi, T., Buck, A. K., Pomper, M. G., Rowe, S. P., & Lapa, C. (2018). The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go? Theranostics, 8(22), 6088-6100. https://doi.org/10.7150/thno.30357